Skip to main content

CORRECTION article

Front. Immunol., 22 February 2023
Sec. Microbial Immunology

Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells

Tao LiTao Li1Xinlong LinXinlong Lin1Binhai ShenBinhai Shen1Wujian ZhangWujian Zhang2Yangyang LiuYangyang Liu3Hongbin LiuHongbin Liu1Ye WangYe Wang3Lijun ZhengLijun Zheng3Fachao Zhi*Fachao Zhi1*
  • 1Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Institute of Gastroenterology of Guangdong Province, Nanfang Hospital, Southern Medical University, Guangzhou, China
  • 2Department of General Surgery of the First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Haerbin, China
  • 3Guangzhou ZhiYi Biotechnology Co. Ltd., Guangzhou, China

A Corrigendum on
Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells.

By Li T, Lin X, Shen B, Zhang W, Liu Y, Liu H, Wang Y, Zheng L and Zhi F (2022) Front. Immunol. 13:1047570. doi: 10.3389/fimmu.2022.1047570

In the published article, there was an error in the legends for Figure 1 to Figure 6 as published. The order of Figure 1 to Figure 6 were all incorrect, and all their citations in the text were not listed in sequential order. The corrected figures and legends appears below.

FIGURE 1
www.frontiersin.org

Figure 1 The intestinal abundance of A muciniphila was decreased in patients and mice with NAFLD-HCC (STAM at 20 weeks) (A) The relative abundance of A muciniphila in patients with NAFLD or NAFLD-HCC and healthy controls by qPCR (n=6). *P<0.05 by unpaired Student’s t test. (B) Comparison of the faecal microbiota between STAM at 20 weeks and controls at the species level by 16S rRNA sequencing. (C) LEfSe analysis of the faecal microbiota between the STAM at 20 weeks and healthy controls. Cladogram displays the taxonomic tree of differentially abundant taxa. Histogram represents the LDA scores of bacteria with significant differential abundance between the compared groups, identified by different colors. (D) The proportion of Akkermansia in the faecal microbiota was compared. (E) qPCR validation of the abundance of A muciniphila in STAM at 20 weeks and control. (F) FISH detection of A muciniphila on the surface of the colon from STAM mice at 4, 10, 16, 20 weeks of age. Data are presented as the mean ± SEM and were analysed by unpaired Student’s t test. NAFLD, non-alcoholic fatty liver disease; HCC, hepatocellular carcinoma; STAM, streptozotocin+high fat diet-treated mice.

In the published article, there was also an error with the figure citations. The figure citations in the text were not listed in sequential order in the Results part.

Corrections have been made through out the article to correct the figure citations.

Figure 4 was corrected to Figure 1, Figure 5 was corrected to Figure 2, Figure 1 was corrected to Figure 3, Figure 2 was corrected to Figure 4, Figure 6 was corrected to Figure 5, Figure 3 was corrected to Figure 6.

FIGURE 2
www.frontiersin.org

Figure 2 The STAM model of diabetes and high fat diet leading to NASH and HCC. (A, B) By 20 weeks, male mice develop numerous liver tumors (n=6). Macroscopic image of the (A) back and (B) front side of liver surface. The serum levels of blood glucose (C) and ALT which were detected by ELISA (D) of the STAM mice were elevated. (E) STAM mice progressed with increased NASH activity scores (NAS) from 10 weeks of age. (F) Paraffin-embedded and frozen mouse liver sections were stained with haematoxylin and eosin (H&E) to determine liver histology (Scale bars, 50 µm). ALT, alanine aminotransferase. *P<0.05 vs STAM group by unpaired Student’s t test.

FIGURE 3
www.frontiersin.org

Figure 3 Supplementation with A muciniphila isolated from breast milk but not from stool improved nonalcoholic steatohepatitis in STAM mice. (A) Experimental design and protocol (n=6). (B) Representative macroscopic image of the liver surface and (C) histological images of liver tissues by H&E staining. Scale bars, 50 µm. (D) Steatosis, inflammation score and ballooning score were evaluated in the livers of STAM mice at 10 weeks of age. (E) The total NASH score was calculated by combining the sum of steatosis score, inflammation score, and ballooning score (n=6/group). (F) Oil-red stained liver tissues of STAM mice with or without A muciniphila adminstration. Scale bars, 50 µm. The serum ALT (G), AST, triglyceride, blood glucose and GLP-1 (H-K) levels were measured. Data represent mean ± SEM of two pooled experiments. *P<0.05 vs STAM group by unpaired Student’s t test. ns, not significant. AKK, Akkermansia muciniphila; ALT, alanine aminotransferase; AST, aspertate aminotransferase; GLP-1, glucagon-like peptide-1.

FIGURE 4
www.frontiersin.org

Figure 4 A muciniphila administration blunted hepatocarcinogenesis in STAM mice. (A) Experimental design and protocol. STAM mice were treated with A muciniphila or saline (Control) starting at 10 weeks of age for 10 weeks, and were killed at 20 weeks of age (n=6/group). (B) Macroscopic image of the liver surface (arrowheads: tumor) and histological images of liver tissues by H&E staining (dashed circle: tumor). Scale bars, 200 µm. (C) The total number of tumor nodules on the liver surface and the maximum diameter of the tumor nodules were compared between the groups. (D) The number of mice developed with liver tumor were counted. The serum levels of (E) ALT, AST, (F) GLP-1, (G) IL-6 and (H) insulin of the STAM mice (20 weeks of age) were measured. (H) The blood glucose were recorded every week. (I) The body weight was recorded every 4 days. Data represent mean ± SEM of two pooled experiments. *P<0.05 by unpaired Student’s t test. ns, not significant. STZ, streptozotocin; STAM, streptozotocin + high fat diet-treated mice; AKK, Akkermansia muciniphila; AST, aspertate aminotransferase; ALT, alanine aminotransferase; GLP-1, glucagon-like peptide-1.

FIGURE 5
www.frontiersin.org

Figure 5 A muciniphila increases NKT cell but reduces macrophage infiltration and inflammatory cytokines in the livers of STAM. (A) Quantification of subgroups of T cells and (B) macrophages by flow cytometry. The percent of (C) CD8+ T cells, NKT cells, (D) monocytes and macrophages in the liver were evaluated. (E) Representative CXCR6 staining in hepatic NKT cells from three independent experiments. Relative mRNA levels of (F) CXCL16 in the liver were determined by real-time PCR and normalized to GAPDH. Data represent mean ± SEM of two pooled experiments (n=6/group). (G) Immunofluorescent staining for macrophages (Scale bars, 50 µm). (H) The infiltration macrophages in the liver were counted (vs healthy control group). (I) Relative mRNA levels of MCP-1, TNF-α and IL-1β in the liver were determined by real-time PCR and normalized to GAPDH. Data represent mean ± SEM of two pooled experiments (n=6/group). AKK, Akkermansia muciniphila. MCP-1, monocyte chemoattractant protein-1. *P<0.05 vs STAM group by unpaired Student’s t test.

FIGURE 6
www.frontiersin.org

Figure 6 A muciniphila inhibit NASH-related HCC through NKT cells. (A) Experimental design and protocol. CD1d−/− (n=6), CXCR6−/− (n=6) or wild-type mice (n=4 or 5) were treated with A muciniphila, a-GalCer (postive control) or saline (placebo-control) for 10 weeks starting at 10 weeks of age twice a day. Mice were killed at 20 weeks of age. (B) Macroscopic images of the liver surface (arrowheads: tumor). (C, D) The total number of tumor nodules on the liver surface were counted and the maximum diameter of the tumor nodules in the liver were measured. (E) Experimental design and protocol of in vivo experiments. (F) The fraction of NKT cells in the splenocytes was cultured with HepG2 cell conditioned medium with or without A muciniphila for 72 hours. (G, H) The percentage of apoptotic HepG2 cells was measured by flow cytometry. Data represent mean ± SEM of two pooled experiments. (I) The mRNA expression of caspase 3 in HepG2 cells was detected by qPCR. *P < 0.05. **p<0.001, ***p<0.0001 by unpaired Student’s t test. STAM, streptozotocin + high fat diet-treated mice; AKK, Akkermansia muciniphila; ns, not significant.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: cancer progression, Akkermansia muciniphila, tumor immune surveillance, nonalcoholic fatty liver disease, hepatocellular carcinoma - metabolic syndrome - non-alcoholic fatty liver disease (NAFLD) - non-alcoholic steatohepatitis - NASH-HCC

Citation: Li T, Lin X, Shen B, Zhang W, Liu Y, Liu H, Wang Y, Zheng L and Zhi F (2023) Corrigendum: Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells. Front. Immunol. 14:1139000. doi: 10.3389/fimmu.2023.1139000

Received: 06 January 2023; Accepted: 27 January 2023;
Published: 22 February 2023.

Edited and Reviewed by:

Changyong Cheng, Zhejiang A & F University, China

Copyright © 2023 Li, Lin, Shen, Zhang, Liu, Liu, Wang, Zheng and Zhi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Fachao Zhi, zhifc41532@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.